Sign inJoin waitlistJoin the waitlist

Patrik Pipkorn

Associate Professor of Otolaryngology · Washington University in St. Louis

Credentials: · · · · · ·

History

Washington University in St. Louis
Present

Washington University in St. Louis
2017
Washington University School of Medicine
2015–2016
University of California Davis Health
2014–2015
University of Cape Town
Head and NeckUntil 2014
2013–2014
Central Hospital
2012–2013
Otolaryngology - Head and Neck Surgery
Washington University/B-JH/SLCH Consortium
2007–2012
University of Gothenburg
2007
University of Michigan
2005
Albert-Ludvig Universität
2003–2004
University of Gothenburg

Research

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Clinical Cancer Research · 2020 · 335 citations
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer
Science Immunology · 2023 · 104 citations
Cellular states are coupled to genomic and viral heterogeneity in HPV-related oropharyngeal carcinoma
Nature Genetics · 2023 · 98 citations

Ryan Jackson
92 papers
Sidharth Puram
72 papers · 1 as a fellow
Jason Rich
47 papers
Joseph Zenga
43 papers · 9 as a resident
Wade Thorstad
32 papers
Jose Zevallos
31 papers
Randal Paniello
31 papers
Douglas Adkins
30 papers
Paul Zolkind
25 papers · 3 as a fellow
Peter Oppelt
23 papers
Evan Graboyes
20 papers · 2 as a fellow
Jake Lee
17 papers · 16 as a resident

Clinical trials

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Sub-investigator · Not yet recruiting · Phase 1, Phase 2
Washington University School of Medicine
2026–2033
The Minimalist Trial-2
Sub-investigator · Recruiting · Phase 2
Washington University School of Medicine
2025–2033
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Sub-investigator · Recruiting · Phase 2
Washington University School of Medicine
2021–2027